Key Points
- CFO Ben Taylor sold 13,426 shares on Feb. 18 at an average price of $3.08 for $41,352, leaving him with 1,195,349 shares (a 1.11% decrease); the sale was disclosed in an SEC filing.
- Recursion stock recently traded around $3.47 (below its 50- and 200-day moving averages) with a market cap of about $1.8B and a one-year range of $2.98–$10.60; analysts hold a consensus Hold rating and an average target of roughly $9.40.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CFO Ben Taylor sold 13,426 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total transaction of $41,352.08. Following the transaction, the chief financial officer directly owned 1,195,349 shares of the company's stock, valued at $3,681,674.92. This represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Recursion Pharmaceuticals Stock Performance
RXRX traded down $0.26 during midday trading on Friday, hitting $3.47. 10,271,253 shares of the company were exchanged, compared to its average volume of 21,401,586. The company's 50 day simple moving average is $4.27 and its 200 day simple moving average is $4.78. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -1.93 and a beta of 0.95. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.98 and a 1-year high of $10.60.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average target price of $9.40.
Get Our Latest Report on RXRX
Institutional Trading of Recursion Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of RXRX. TD Waterhouse Canada Inc. increased its holdings in Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company's stock valued at $29,000 after buying an additional 2,200 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $31,000. Sequoia Financial Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $41,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Recursion Pharmaceuticals by 97.2% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company's stock worth $46,000 after acquiring an additional 4,446 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company's stock valued at $47,000 after acquiring an additional 4,403 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
